Publication:
Performance and Dimensionality of Pretreatment MRI Radiomics in Rectal Carcinoma Chemoradiotherapy Prediction

dc.contributor.authorMarinkovic, Mladen (57222259689)
dc.contributor.authorStojanovic-Rundic, Suzana (23037160700)
dc.contributor.authorStanojevic, Aleksandra (58309472800)
dc.contributor.authorTomasevic, Aleksandar (56630429500)
dc.contributor.authorJankovic, Radmila (57192010824)
dc.contributor.authorZoidakis, Jerome (6506081730)
dc.contributor.authorCastellví-Bel, Sergi (57193218784)
dc.contributor.authorFijneman, Remond J. A. (55879267200)
dc.contributor.authorCavic, Milena (39760938900)
dc.contributor.authorRadulovic, Marko (57200831760)
dc.date.accessioned2025-06-12T11:57:43Z
dc.date.available2025-06-12T11:57:43Z
dc.date.issued2024
dc.description.abstract(1) Background: This study aimed to develop a machine learning model based on radiomics of pretreatment magnetic resonance imaging (MRI) 3D T2W contrast sequence scans combined with clinical parameters (CP) to predict neoadjuvant chemoradiotherapy (nCRT) response in patients with locally advanced rectal carcinoma (LARC). The study also assessed the impact of radiomics dimensionality on predictive performance. (2) Methods: Seventy-five patients were prospectively enrolled with clinicopathologically confirmed LARC and nCRT before surgery. Tumor properties were assessed by calculating 2141 radiomics features. Least absolute shrinkage selection operator (LASSO) and multivariate regression were used for feature selection. (3) Results: Two predictive models were constructed, one starting from 72 CP and 107 radiomics features, and the other from 72 CP and 1862 radiomics features. The models revealed moderately advantageous impact of increased dimensionality, with their predictive respective AUCs of 0.86 and 0.90 in the entire cohort and 0.84 within validation folds. Both models outperformed the CP-only model (AUC = 0.80) which served as the benchmark for predictive performance without radiomics. (4) Conclusions: Predictive models developed in this study combining pretreatment MRI radiomics and clinicopathological features may potentially provide a routine clinical predictor of chemoradiotherapy responders, enabling clinicians to personalize treatment strategies for rectal carcinoma. © 2024 by the authors.
dc.identifier.urihttps://doi.org/10.3390/jcm13020421
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85183386946&doi=10.3390%2fjcm13020421&partnerID=40&md5=5e044751b0453fbf7f60cab71dea8b9e
dc.identifier.urihttps://remedy.med.bg.ac.rs/handle/123456789/2039
dc.subjectchemoradiotherapy
dc.subjectMRI
dc.subjectneoadjuvant
dc.subjectradiomics
dc.subjectrectal carcinoma
dc.titlePerformance and Dimensionality of Pretreatment MRI Radiomics in Rectal Carcinoma Chemoradiotherapy Prediction
dspace.entity.typePublication

Files